<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21397" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ethylenediaminetetraacetic Acid (EDTA)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>George</surname>
            <given-names>Tom</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Brady</surname>
            <given-names>Mark F.</given-names>
          </name>
          <aff>Alpert Medical School of Brown University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tom George declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mark Brady declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21397.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Ethylenediaminetetraacetic acid (EDTA) is a medication used in the management and treatment of heavy metal toxicity. It is in the chelating class of drugs. This activity outlines and reviews the indications, actions, and contraindications for EDTA as a valuable agent in managing lead toxicity. This activity will highlight the mechanism of action, side effect profile, and other key factors such as dosing, pharmacokinetics, and monitoring pertinent for members of the healthcare team in the use of EDTA.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the indications for EDTA.</p></list-item><list-item><p>Identify the most common adverse effects associated with EDTA therapy.</p></list-item><list-item><p>Explain the importance of monitoring for patients on EDTA therapy, including renal function tests.</p></list-item><list-item><p>Identify the mechanism of action of EDTA.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21397&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21397">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21397.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Ethylenediaminetetraacetic acid (EDTA, edetate calcium disodium, calcium disodium versenate) is a chelation agent used for&#x000a0;heavy&#x000a0;metal toxicity. EDTA, which was first synthesized in the mid-1930s, has non-pharmacologic and pharmacologic purposes. As a pharmacologic agent, EDTA is used as calcium disodium edetate, which prevents it from binding calcium in the body. Another form, edetate disodium, has a markedly improved ability to bind calcium; this form is no longer used for chelation therapy due to the high risk for hypocalcemia. As a non-pharmacologic agent, EDTA is used in many different industries to remove toxic metal ions. It is commonly used in the cosmetic and food industry and has many applications within scientific laboratories.<xref ref-type="bibr" rid="article-21397.r1">[1]</xref></p>
        <p>
<bold>Lead Poisoning</bold>
</p>
        <p>Currently, EDTA is FDA-approved for the treatment of lead poisoning in adults and children. EDTA has the ability to bind lead tightly and is more effective than other common chelators.</p>
        <p>EDTA is also used in a diagnostic test to assess levels of lead present within patients. The lead mobilization test is performed by administering 2 grams of EDTA through the intravenous or intramuscular route. Patients have a positive lead mobilization test if, in the following 24 hours, they excrete more than 6 grams of lead in their urine. The lead mobilization test allows clinicians to have a more accurate total body lead level and further guide treatment with chelation agents.<xref ref-type="bibr" rid="article-21397.r2">[2]</xref></p>
        <p>While not approved by the FDA, EDTA has the ability to bind other heavy metals within the body, including zinc, cadmium, mercury, and iron. Many cases have been reported where EDTA is used to bind other toxic metals, forming a soluble compound&#x000a0;that allows excretion through the urine.<xref ref-type="bibr" rid="article-21397.r3">[3]</xref><xref ref-type="bibr" rid="article-21397.r4">[4]</xref></p>
        <p>
<bold>Coronary Artery Disease/Atherosclerosis</bold>
</p>
        <p>While limited, there have been reports of EDTA being beneficial to reduce coronary artery disease.&#x000a0;With the negative effects of heavy metals on the cardiovascular system, EDTA has been proposed as a useful agent against the development of atherosclerosis. Additionally, edetate disodium has a high affinity for calcium within the body. It is thought that chelation therapy&#x000a0;might be beneficial by scavenging the calcium present within fatty, atherosclerotic deposits.<xref ref-type="bibr" rid="article-21397.r5">[5]</xref><italic toggle="yes"><bold>&#x000a0;</bold></italic></p>
        <p>
<bold>Neurotoxicity</bold>
</p>
        <p>Heavy metals have the ability to produce reactive agents within the body that lead to an inflammatory cascade. The various cytokines and inflammatory agents have negative effects on the nervous system and can lead to neurotoxicity.&#x000a0; Calcium disodium edetate can be useful for the management of certain neurodegenerative disorders. By chelating metal ions, further inflammatory changes are prevented from taking place.<xref ref-type="bibr" rid="article-21397.r6">[6]</xref></p>
      </sec>
      <sec id="article-21397.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Chelation agents function by forming bonds with various metal ions, including calcium, zinc, lead, etc. After these bonds are formed, a soluble chelate-metal complex is created that can be excreted from the body. In a similar method, EDTA has a complex structure that allows it to bind various metals. The molecular composition of EDTA consists of multiple oxygen molecules, which function to donate electrons and form coordination complexes with metal ions. When calcium disodium edetate binds to metals, the calcium is displaced from the structure. The bonds formed with the metals are extremely strong and prevent further toxic effects&#x000a0;from occurring before excretion out of the body.<xref ref-type="bibr" rid="article-21397.r7">[7]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>
<bold>Absorption</bold>
</p>
        <p>EDTA is rapidly absorbed through intravenous access and moves into the plasma and interstitial fluids. Oral administration is avoided due to very low (less than 5%) absorption and elevated lead concentrations within the gastrointestinal tract.</p>
        <p>
<bold>Distribution</bold>
</p>
        <p>EDTA is distributed throughout the entire extracellular compartment. Within the blood, the molecule stays within the plasma. It has an ionic form preventing it from entering into cells.</p>
        <p>
<bold>Metabolism/Excretion</bold>
</p>
        <p>After IV administration, calcium EDTA largely goes unmetabolized and is excreted in its administered form through the kidneys. Similarly, the chelate-metal complexes will be quickly excreted in the urine. The half-life is around 20&#x000a0;to 60 minutes. The kidneys can filter out the drug&#x000a0;and secrete it into the tubular lumen.<xref ref-type="bibr" rid="article-21397.r8">[8]</xref></p>
      </sec>
      <sec id="article-21397.s4" sec-type="Administration">
        <title>Administration</title>
        <p>EDTA is poorly absorbed through the gastrointestinal tract and therefore is administered through intramuscular injection or intravenous infusion.</p>
        <p>Due to side effects, chelation therapy is generally not used in adults with lead levels less than 45mcg/dl. However, in cases where patients are symptomatic, chelation&#x000a0;is recommended.<xref ref-type="bibr" rid="article-21397.r9">[9]</xref>&#x000a0;According to the manufacturer's prescribing information, EDTA is dosed based on body surface area and renal function status.</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>Lead poisoning (20mcg/dl - 70mcg/dl): 1000 mg/m^2 daily given IV or IM</p>
        <p>Lead poisoning (&#x0003e;70mcg/dl): EDTA is combined with dimercaprol; EDTA is administered before dimercaprol</p>
        <p>Adults with lead nephropathy: 500 mg/m^2 every 24 hours for 5 days for creatinine levels of 2&#x000a0;to 3 mg/dl; 500 mg/m^2 every 48 hours for 3 doses for creatinine levels of 3&#x000a0;to 4 mg/dl; 500 mg/m^2 weekly for creatinine levels above 4 mg/dl</p>
        <p>
<bold>Pediatric Dosing</bold>
</p>
        <p>In children, patients are commonly given the combination of EDTA and dimercaprol. Chelation therapy is essential in patients with blood lead levels over 45 mcg/dl</p>
        <p>Lead poisoning (45 mcg/dl&#x000a0;to 70 mcg/dl): 25 mg/kg/day for 5 days <xref ref-type="bibr" rid="article-21397.r10">[10]</xref></p>
        <p>Lead poisoning (&#x0003e;70mcg/dl): IV administration of EDTA at 50 mg/kg/day in six doses</p>
        <p>In children with cerebral edema, intravenous administration is avoided due to an increase in intracranial pressure. To avoid this, intramuscular administration is used in these patients</p>
      </sec>
      <sec id="article-21397.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>There are multiple adverse effects related to the use of EDTA. These side effects are dependent on various factors, including dosage, renal function, and frequency of administration. The most commonly recognized adverse effect is renal toxicity. The toxic effects can manifest as acute tubular necrosis, renal failure, anuria, and proteinuria.&#x000a0;Both intramuscular and intravenous routes of administration were shown to increase blood urea nitrogen in more than 25% of patients.<xref ref-type="bibr" rid="article-21397.r9">[9]</xref><xref ref-type="bibr" rid="article-21397.r10">[10]</xref><xref ref-type="bibr" rid="article-21397.r11">[11]</xref></p>
        <p>Additionally, calcium EDTA has a strong affinity for zinc, which can lead to a zinc deficiency. The amount of zinc lost from the body was shown to be negatively correlated with weight. A study assessing the efficacy of calcium disodium edetate found that smaller children were losing a larger proportion of zinc than&#x000a0;larger children. The study further reinforced the need to monitor levels of zinc during chelation therapy.<xref ref-type="bibr" rid="article-21397.r11">[11]</xref></p>
        <p>Other side effects include fever, nausea, vomiting, chills, fatigue, arthralgia, hypotension, arrhythmias, acute tubular necrosis, proteinuria, tremors, headache, cheilosis, bone marrow depression, anemia, and hypercalcemia. Pain at the injection site is a common adverse drug reaction of intramuscular administration.<xref ref-type="bibr" rid="article-21397.r12">[12]</xref></p>
        <p>Administration of edetate calcium disodium must be carefully distinguished from the administration of edetate disodium. Edetate disodium is similar in structure to edetate calcium disodium; however, it is not complexed with calcium. This minor difference protects serum levels of calcium and avoids life-threatening hypocalcemia. Cases have been reported where patients who were incorrectly given edetate disodium&#x000a0;had&#x000a0;seizures and cardiac arrest.<xref ref-type="bibr" rid="article-21397.r13">[13]</xref></p>
      </sec>
      <sec id="article-21397.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>EDTA is contraindicated in patients with renal disease or anuria, as the kidneys eliminate the drug. This may lead to excessive levels of EDTA building up, resulting in further nephrotoxic effects. Additionally, the administration should be avoided in patients with hepatitis. EDTA is classified as a Category B drug and should only be used in pregnant patients if needed. One study showed that EDTA did not produce any teratogenic effects in rats, even at extremely high doses.<xref ref-type="bibr" rid="article-21397.r14">[14]</xref></p>
      </sec>
      <sec id="article-21397.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Many of the adverse effects of EDTA appear to occur in patients given high doses or with preexisting renal disease. Administration of calcium disodium edetate to patients requires monitoring of renal and hepatic function. These should be monitored before, during, and after administration. If patients become anuric or develop increasing creatinine levels, EDTA should be immediately discontinued. Additional urinalysis may be performed to assess for the presence of hematuria or proteinuria. It is also important to monitor zinc levels as&#x000a0;EDTA strongly binds to zinc.<xref ref-type="bibr" rid="article-21397.r15">[15]</xref></p>
      </sec>
      <sec id="article-21397.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Currently, no antidotes are available for EDTA. In patients who have cerebral edema, increases in intracranial pressure should be treated immediately with osmotic agents. Patients with nephrotoxicity should be given fluids to ensure hydration and be monitored for urine output. Renal function should be continuously monitored even after the development of toxicity. Overall, patients who develop signs or symptoms of toxicity should immediately be discontinued from the drug.</p>
      </sec>
      <sec id="article-21397.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Heavy metal toxicity&#x000a0;is a major concern in both adult and pediatric populations. This is of special concern to the pediatric population as lead poisoning can affect cognition and neurodevelopment. Due to the permanent toxic effects of heavy metals, patients must be treated quickly and appropriately. Adequate management by a team of healthcare professionals plays an important role in decreasing overall morbidity and mortality associated with metal toxicity.</p>
        <p>Healthcare providers involved in the care of a patient being treated with EDTA should be knowledgeable about the pharmacology and adverse effects of the drug. EDTA has the ability to bind various minerals within the body and should be monitored for any adverse effects. Pharmacists should be mindful of the important difference between edetate disodium and calcium disodium edetate to prevent life-threatening hypocalcemia.&#x000a0;Nurses should verify dosing and administration with the pharmacy team and understand the adverse drug reactions mentioned to inform the managing healthcare provider promptly. [Level 5]</p>
        <p>Clinicians should be aware of the&#x000a0;well-known renal toxicity associated with EDTA. Patients with current renal dysfunction or disease should be monitored carefully or moved to a different chelation agent. Social workers can help the family identify any occupational or home exposure to heavy metals and assist in&#x000a0;preventing further exposure. Each member of the interprofessional healthcare team has an important role in treating a patient with EDTA and can significantly reduce the morbidity and mortality associated with heavy metal toxicity.</p>
      </sec>
      <sec id="article-21397.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21397&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21397">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21397/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21397">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21397.s11">
        <title>References</title>
        <ref id="article-21397.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wax</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Current use of chelation in American health care.</article-title>
            <source>J Med Toxicol</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>303</fpage>
            <page-range>303-7</page-range>
            <pub-id pub-id-type="pmid">24113860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21397.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markowitz</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Need for the lead mobilization test in children with lead poisoning.</article-title>
            <source>J Pediatr</source>
            <year>1991</year>
            <month>Aug</month>
            <volume>119</volume>
            <issue>2</issue>
            <fpage>305</fpage>
            <page-range>305-10</page-range>
            <pub-id pub-id-type="pmid">1907320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21397.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakthithasan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>L&#x000e9;vy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Poupon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garnier</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A comparative study of edetate calcium disodium and dimercaptosuccinic acid in the treatment of lead poisoning in adults.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>56</volume>
            <issue>11</issue>
            <fpage>1143</fpage>
            <page-range>1143-1149</page-range>
            <pub-id pub-id-type="pmid">29889577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21397.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corsello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fulgenzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vietti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferrero</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>The usefulness of chelation therapy for the remission of symptoms caused by previous treatment with mercury-containing pharmaceuticals: a case report.</article-title>
            <source>Cases J</source>
            <year>2009</year>
            <month>Nov</month>
            <day>18</day>
            <volume>2</volume>
            <fpage>199</fpage>
            <pub-id pub-id-type="pmid">19946446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21397.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamas</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Issa</surname>
                <given-names>OM</given-names>
              </name>
            </person-group>
            <article-title>Edetate Disodium-Based Treatment for Secondary Prevention in Post-Myocardial Infarction Patients.</article-title>
            <source>Curr Cardiol Rep</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>20</fpage>
            <pub-id pub-id-type="pmid">26797807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21397.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fulgenzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferrero</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>EDTA Chelation Therapy for the Treatment of Neurotoxicity.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Feb</month>
            <day>26</day>
            <volume>20</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">30813622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21397.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sears</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Chelation: harnessing and enhancing heavy metal detoxification--a review.</article-title>
            <source>ScientificWorldJournal</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>219840</fpage>
            <pub-id pub-id-type="pmid">23690738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21397.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porru</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alessio</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The use of chelating agents in occupational lead poisoning.</article-title>
            <source>Occup Med (Lond)</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-8</page-range>
            <pub-id pub-id-type="pmid">8672793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21397.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Chae</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Ha</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Jeon</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>YS</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and management of lead exposure.</article-title>
            <source>Ann Occup Environ Med</source>
            <year>2015</year>
            <volume>27</volume>
            <fpage>30</fpage>
            <pub-id pub-id-type="pmid">26677413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21397.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <article-title>Treatment guidelines for lead exposure in children. American Academy of Pediatrics Committee on Drugs.</article-title>
            <source>Pediatrics</source>
            <year>1995</year>
            <month>Jul</month>
            <volume>96</volume>
            <issue>1 Pt 1</issue>
            <fpage>155</fpage>
            <page-range>155-60</page-range>
            <pub-id pub-id-type="pmid">7596706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21397.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Chisolm</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Lead, zinc and copper decorporation during calcium disodium ethylenediamine tetraacetate treatment of lead-poisoned children.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1986</year>
            <month>Dec</month>
            <volume>239</volume>
            <issue>3</issue>
            <fpage>829</fpage>
            <page-range>829-35</page-range>
            <pub-id pub-id-type="pmid">3098962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21397.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanigan</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Yamarik</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Final report on the safety assessment of EDTA, calcium disodium EDTA, diammonium EDTA, dipotassium EDTA, disodium EDTA, TEA-EDTA, tetrasodium EDTA, tripotassium EDTA, trisodium EDTA, HEDTA, and trisodium HEDTA.</article-title>
            <source>Int J Toxicol</source>
            <year>2002</year>
            <volume>21 Suppl 2</volume>
            <fpage>95</fpage>
            <page-range>95-142</page-range>
            <pub-id pub-id-type="pmid">12396676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21397.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baxter</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Krenzelok</surname>
                <given-names>EP</given-names>
              </name>
            </person-group>
            <article-title>Pediatric fatality secondary to EDTA chelation.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>46</volume>
            <issue>10</issue>
            <fpage>1083</fpage>
            <page-range>1083-4</page-range>
            <pub-id pub-id-type="pmid">18949650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21397.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schardein</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Sakowski</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Petrere</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Humphrey</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Teratogenesis studies with EDTA and its salts in rats.</article-title>
            <source>Toxicol Appl Pharmacol</source>
            <year>1981</year>
            <month>Dec</month>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>423</fpage>
            <page-range>423-8</page-range>
            <pub-id pub-id-type="pmid">6800065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21397.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>REUBER</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>BRADLEY</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Acute versenate nephrosis; occurring as the result of treatment for lead intoxication.</article-title>
            <source>JAMA</source>
            <year>1960</year>
            <month>Sep</month>
            <day>17</day>
            <volume>174</volume>
            <fpage>263</fpage>
            <page-range>263-9</page-range>
            <pub-id pub-id-type="pmid">14437478</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
